Asked by: Andrew Mitchell (Conservative - Sutton Coldfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that eligible women take up breast cancer screening in Sutton Coldfield constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Through our National Health Service screening programmes, we can reduce mortality and morbidity from cancer in the population who appear healthy and have no symptoms, by detecting conditions at an earlier, more treatable stage. Each year, over 15 million people are invited for screening, with over 10 million taking up the invitation.
In Birmingham and Solihull, between 2022/23 and 2023/24 there has been an improvement of 4.93% in breast cancer screening uptake in 53 to 70 year old people.
In Sutton Coldfield, the breast screening is offered to all eligible cohorts in line with service specifications of the NHS Breast Screening Programme. In this constituency, uptake and coverage are stable and constituents can access screening at both static and mobile facilities. There is a dedicated focus on reducing health inequalities, supporting access, and informing eligible patients to actively take up their screening appointment and offer.
The breast screening service in Sutton Coldfield is currently undertaking a targeted text messaging initiative targeting eligible patients that have not attended their screening invitation. This includes the offer to rebook their screening appointment and a link to bilingual breast screening videos to support education and awareness. A follow-up text message survey is also being used to explore barriers to attendance and motivating factors, with insights informing ongoing service development.
Other initiatives to increase uptake in the area include:
a dedicated general practice toolkit to support and inform health promotion messaging;
a breast screening resource pack for care homes to support staff in promoting screening awareness and facilitating uptake amongst eligible residents; and
a cancer bus initiative promoting a range of services including breast cancer screening.
Asked by: Lorraine Beavers (Labour - Blackpool North and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of integrating all at risk screening for breast cancer into the National NHS Breast Screening Programme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The new and world-leading NHS National Inherited Cancer Predisposition Registry (NICPR), part of the National Disease Registration Service, will help the National Health Service to deliver proactive, targeted prevention, surveillance, and earlier diagnosis for people and their families. Women at Very High Risk (VHR) of breast cancer are now identified within the NICPR and referred into the NHS Breast Screening Programme (NHSBSP), which has enabled reconciliation to ensure that all identified women are safely referred into the programme. This is a step towards a fully electronic referral VHR process into the NHSBSP.
The Government is advised on all screening matters by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which is made up of leading medical and screening experts. Where the UK NSC is confident that offering screening provides more good than harm, they recommend a screening programme.
In 2022 the remit of the UK NSC was expanded to include targeted, and risk stratified screening, in addition to population screening. So far, the UK NSC has not made a recommendation for targeted screening of women at a moderate or high risk of breast cancer.
Currently, if women reach the criteria for moderate or high- risk screening with surveillance recommended, this is offered as part of screening provision managed locally with NHS trusts.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to raise awareness amongst men in Yeovil constituency about the risks of breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service in England encourages everyone, including men in the Yeovil constituency, to check their breast and chest regularly for firm lumps, changes or thickened areas of tissue, and to consult their general practitioner straight away if they have any concerns.
To increase knowledge of cancer symptoms, and address barriers to acting on them, the NHS runs Help Us Help You campaigns. These campaigns focus on recognising a range of symptoms, as well as encouraging body awareness, to help people spot symptoms across a wide range of cancers, including breast cancer, at an earlier stage.
NHS England and other NHS organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including breast cancer. Further information on breast cancer symptoms in men can be found on the NHS.UK website, which is available at the following link:
https://www.nhs.uk/conditions/breast-cancer-in-men/symptoms-of-breast-cancer-in-men/
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reducing the starting age for routine mammograms to 40.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Each year, over 15 million people are invited for screening by National Health Service screening programmes, with over 10 million taking up the invitation. Through our NHS screening programmes, we can reduce mortality and morbidity from cancer and other conditions in the population who appear healthy and have no symptoms, by detecting conditions at an earlier, more treatable stage.
We are guided by the independent scientific advice of the UK National Screening Committee (UK NSC) on all screening matters. It is only where there is robust evidence that an offer to screen provides more good than harm that a screening programme is recommended.
As screening programmes can also cause harms, each of the adult screening programmes has both an upper and lower age range, within which there is good scientific evidence that the benefits of screening outweigh the harms.
The NHS Breast Screening Programme does not currently offer screening to women younger than the age of 50 for breast cancer due to the lower risk of women under this age developing breast cancer, and the fact that women below 50 tend to have denser breasts tissue. The density of breast tissue reduces the ability of getting an accurate mammogram, the accepted screening test for breast cancer.
There is therefore a risk of unnecessary treatment and distress for women who do not have breast cancer, but who would be subjected to invasive and painful medical treatments and diagnostic tests.
We are in line with most European countries, most of whom screen women between the ages of 50 to 69 years old.
The UK NSC recognises that screening programmes are not static and that, over time, they may need to change to be more effective. Work is underway within the breast screening programme to investigate the possibility of routinely screening below the currently recommended age. The AgeX research trial has been looking at the effectiveness of offering some women one extra screen between the ages of 47 and 49 years old.
It is the biggest trial of its kind ever to be undertaken and will provide robust evidence about the effectiveness of screening in these age groups, including the benefit and harms. The UK NSC will review the publication of the age extension trial when it reports.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that people over the age of 71 can request a breast cancer screening in Yeovil constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
People in Yeovil who are over the age of 71 years old can request breast cancer screening once every three years by contacting their local National Health Service breast screening programme directly.
They will be offered an appointment at either the nearest mobile screening van, which rotate around the county on a three-yearly cycle, or the static screening centre at Musgrove Park Hospital in Taunton.
Asked by: Laura Kyrke-Smith (Labour - Aylesbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding he plans to provide for treatments for secondary breast cancer in each of the next three years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the National Cancer Plan will support people with secondary breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan, published 4 February 2026, will transform outcomes for people with secondary breast cancer.
The National Health Service is piloting the use of self-referral breast cancer pathways to streamline diagnostic pathways using the NHS App and NHS 111 online service. This is in addition to the Government’s commitment for the NHS to deliver 9.5 million additional tests by 2029 through a £2.3 billion investment in diagnostics. We are also ensuring as many community diagnostic centres as possible are fully operational and open 12 hours a day, seven days a week.
To improve the diagnosis of breast cancer, the NHS will harness 'circulating tumour DNA' tests for breast cancer, which can pick up relapse months earlier. This will accelerate clinical decisions and allow patients to start the most effective treatment faster.
The NHS will monitor the emerging evidence from the BRAID trial, which aims to determine whether additional imaging with one of several types of scans, is helpful in diagnosing breast cancer in women with dense breast tissue. This will target screening programmes at women who are at greater risk of cancer.
The NHS is also improving the experience of those with a cancer diagnosis. Every patient diagnosed with cancer will be supported through a full neighbourhood-level personalised care package, covering mental and physical health as well as any practical or financial concerns. For people with secondary breast cancer, this will be a step forward in building care around them, their needs, their lives, and their families.
We will harness data, as we begin counting metastatic disease, starting with breast cancer, so that people living with incurable cancer are properly recognised and better supported.
Through these National Cancer Plan actions, we will ensure that people with secondary breast cancer have faster diagnoses and treatment, access to the latest treatments and technology, and high-quality support throughout their journey, while we work to drive up this country’s cancer survival rates.
Asked by: Lord Freyberg (Crossbench - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what is the current average time from test request to result for tests provided by NHS England's genomic medicine laboratories; and what assessment they have made of the impact of those turnaround times on patient access to appropriate treatment for (1) SOD1 testing in motor neurone disease, (2) germline BRCA1/2 testing in hereditary female cancers, and (3) homologous recombination deficiency testing in breast cancer and ovarian cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In December 2025, the average turnaround time for genomic tests processed through the NHS Genomic Laboratory Hubs were 42 days for the test code which includes SOD1 analysis for motor neuron disease, as well as other clinical indications, 37 to 42 days for germline BRCA1/2 testing, and 22 days for homologous recombination deficiency (HRD) testing for ovarian carcinomas. These are within the national targets of 42 days for the test code which includes SOD1 analysis for motor neuron disease and BRCA1/2 and 28 days for HRD, supporting timely clinical decision‑making. As genomic results directly inform treatment choices for motor neurone disease, hereditary female cancers, and ovarian carcinoma, maintaining these turnaround times is essential to ensuring patients can access appropriate therapies without delay.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the training provided to GPs on prescribing risk-reducing drugs to women at increased risk of breast cancer.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
General practitioners (GPs) are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence, to ensure that they can continue to provide high quality care to all patients.
We are investing an additional £1.1 billion in GPs, bringing total spend on the GP Contract to £13.4 billion in 2025/26, the biggest increase in over a decade. The 8.9% boost to the GP Contract in 2025/26 is bigger than the 5.8% growth to the National Health Service budget as a whole, demonstrating our commitment to shifting resources to the community.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a national register to capture and integrate the data of all women at increased risk of breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Disease Registration Service (NDRS) in NHS England provides England’s national resource for data and analytics on cancer, rare diseases, and congenital conditions.
The NDRS already serves as a national register for women at very high risk of breast cancer. NDRS curates and quality assures the collected data to ensure sufficient accuracy and completeness. The NDRS works closely with the very high risk National Breast Screening Programme to ensure safe and robust identification of women at very high risk of cancer. The integration of this data within the wider NDRS cancer data infrastructure maximises the use of this data which helps with service planning, evaluation, and improvement, and reduces the fragmentation and siloing that would occur with standalone registers.